Drug Trial Radar · NCT02183025
Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea
Last checked: Nov 20, 2026Latest source record: Aug 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
337
Actual
Start
Jan 1998
Primary completion
Apr 1999
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jul 8, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To access the efficacy and safety of Meloxicam 7.5 mg and 15 mg once daily compared with Mefenamic acid 500 mg t.i.d. over a treatment period of 3-5 days, during an observation period of 3 menstrual cycles, for the symptomatic relief of primary dysmenorrhea
Conditions
- Dysmenorrhea
Interventions
Meloxicam 7.5 mgDrug
Meloxicam 15 mgDrug
Mefenamic acid 500 mgDrug
Placebo matching 7.5 mg meloxicamDrug
Placebo matching 15 mg meloxicamDrug
Placebo matching 500 mg mefenamic acidDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of severity of lumbar and/or abdominal pain on a visual analogue scale (VAS)Time frame: Baseline and day 3-5 of each treatment cycle
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.